Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Vaccine
- HIV / AIDs
- Disease
- Therapeutic
- Drug Discovery
- Viral Infection
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 329709
Patent Application U.S. Serial No. 09/007,664, 98/03894, 09,121,587
Inventions shall mean any inventions, ideas, discoveries which are first conceived, discovered or actually reduced to practice before, during and after the performance of the Development Work under the Research and Development Program and are related to the Dengue Vaccine.
Improvements shall mean any improvements to the Dengue Vaccine which are first conceived, discovered or actually reduced to practice during and after the performance of the Development Work under the Research and Development Program.
Dengue is an acute febrile disease caused by the mosquito-borne dengue viruses.
IPSCIO Record ID: 237242
Licensee-Controlled Inventions shall mean the inventions disclosed in the United States patents and foreign equivalents and United States and foreign patent applications listed and all divisions, continuations, continuations in part, reissues, or extensions thereof, any periods of marketing exclusivity relating thereto, and any letters patent that issue thereon. It is understood that certain of the Licensee-Controlled Inventions (the Licensed Licensor Rights) are owned by Licensor and are covered by one or more exclusive licenses or sublicenses to Licensee, directly or indirectly.
US 5,858,775 – Adeno-associated virus materials and methods
US 5,786,211 – Adeno-associated virus materials and methods
US 5,658,785 – Adeno-associated virus materials and methods
US 5,139,941 – AAV transduction vectors
Program Vaccines shall mean any AAV (adeno-associated virus) particle-based vector that contains an HIV-1 gene in the recombinant vector genome and that can act as a prophylactic vaccine against HIV-1.
Proprietary Technology shall mean any Background Technology to the extent it has not previously been disclosed in an issued patent or a published patent application. Background Technology shall mean (i) the rights to make, use, sell, offer for sale, and import the Licensee-Controlled Inventions; (ii) all inventions (whether or not patented or patentable), know-how, techniques, cell lines, data, studies and results of studies and other proprietary information in the possession or control of Licensor at the Effective Date and at any time thereafter during the period in which Licensor remains a direct participant in the Research and Development Program, to the extent bearing upon the Program Vaccines, the Licensee-Controlled Inventions, the Program Inventions, or any of them within the Program Field (as and to the extent the Program Field exists during the period of such direct participation by Licensor); and (iii) know-how and other proprietary information in the possession or control of Licensee at the Effective Date and at any time thereafter during the period in which Licensee remains a direct participant in the Research and Development Program, to the extent useful for the practice of the Licensee-Controlled Inventions within the Program Field (as and to the extent the Program Field exists during the period of such direct participation by Licensee).
Work Plan and Budget shall mean the set of tasks, procedures, protocols, standards, budgets, and target time frames set forth, as such may be amended or supplemented by mutual written agreement of the parties from time to time.
Program Field shall mean the manufacture of one or more of the Program Vaccines through the use of the particular combination of Program Inventions and Background Technology as implemented by Licensor and Licensee under this Agreement during and in the course of the Research and Development Program (as the same may be supplemented or improved by or for Licensor with other inventions or technology from sources other than Licensor or Licensee), solely for distribution in the Public Sector, and the use, sale, offer for sale, and import of such Program Vaccines so manufactured in and to the Public Sector. I
The collaboration agreement is to develop a vaccine to prevent AIDS. The vaccine will utilize Targeted Genetics’ Adeno-Associated Viral Vectors (AAV ) to deliver HIV genes as a novel form of genetic immunization.
IPSCIO Record ID: 275977
The Research and Development Program will involve the systematic design and development of the Program Vaccine for use in the Field. The scope and goals of the Research and Development Program are subject to modification.
Licensor grants the Licensee of Denmark a worldwide, nonexclusive, non sublicensable and nontransferable license during the Research Term to practice the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, solely in connection with activities to be performed by Licensor under the Research and Development Program.
Licensor grants a worldwide, non-exclusive and nontransferable license, with rights to sublicense, under the Licensor Background Technology, the Licensor. Patent Rights and the Joint Patent Rights, to make, have made, use, sell, offer for sale and import Licensee-Combined Vaccines or the Program Vaccines.
IPSCIO Record ID: 375061
BWV-201 is a live attenuated serotype-independent intranasal vaccine candidate for S. pneumoniae induced AOM (Acute Otitis Media). BWV-201 has the ability to transiently colonize the nasopharyngeal cavity and significantly decrease the incidence of AOM and sinusitis in animal models. The vaccine candidate is derived from the noninvasive serotype 19F strain BHN97.
9,265,819 – Live, attenuated Streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease
Streptococcus pneumoniae is the main cause of community acquired pneumonia and meningitis in children and the elderly, and of sepsis in those infected with HIV.
IPSCIO Record ID: 309686
Product means any diagnostic, food safety, premises, prophylactic or therapeutic embodiment to treat Bovine Respiratory Disease (BRD), including Bovine Viral Diarrhea Virus (BVDV), that incorporates, uses or implements Licensor Technology and/or Patent Rights, whether such embodiment was in existence prior to the Effective Date.
Immunological Products means proprietary delipidation-based methods and systems for the production of treatments for viral or bacterial infections, among other ailments, of which Licensor and/or its Affiliate(s) are the owners and/or exclusive licensees having the right to enforce and sublicense.
New Product(s) means any diagnostic, food safety, premises, prophylactic or therapeutic embodiment other than Product(s) that incorporates, uses or implements Licensor Technology and/or Patent Rights and that is ultimately sold by or for Licensee inside the New Field in the Territory,
Licensee Compound means one or more active ingredients directly resulting from Licensor Technology that is selected by Licensee for development and commercialization of Product(s) and/or New Product(s).
Licensee Invention means any Invention by Licensee and/or its Affiliates (other than a joint invention) that is discovered, made, or conceived and reduced to practice during or as a result of the Collaboration Design & Development Program.
Licensee is engaged in the research, development, marketing, manufacturing and distribution of animal health products for use in, on or near live animals.
Field means all applications and uses of the Licensor Technology and Patent Rights for Products. For clarity, Field does not include any human applications or uses.
New Field means all applications and uses of the Licensor Technology and Licensor Patent Rights for New Products. For clarity, New Field does not include any human applications or uses.
IPSCIO Record ID: 328343
AIDS Vaccine means a vaccine which would prevent an infection by Human Immunodeficiency Virus (HIV-1) and/or clinical diseases caused by infection with HIV-1 in humans.
Influenza Vaccine means a vaccine which would prevent an infection and/or significant clinical diseases caused by any influenza virus in humans.
Licensed Product means a bulk or finished AIDS Vaccine or Influenza Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program; provided, however, that if any such vaccine is also capable of being used for treatment of the same human infectious disease, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement.
IPSCIO Record ID: 273437
The Research and Development Program will involve the systematic design and development of the Program Vaccine for use in the Field. The scope and goals of the Research and Development Program are subject to modification.
Licensor grants a worldwide, nonexclusive, nonsublicensable and nontransferable license during the Research Term to practice the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, solely in connection with activities to be performed by Licensee under the Research and Development Program.
Subject to the exercise by Licensee of the Combination Option or Option, Licensor grants to a worldwide, non-exclusive and non-transferable license, with rights to sublicense, under the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, to use, sell, offer for sale and import Combined Vaccine or the Program Vaccine during the Term.
